FDA finalized guidance on identity and safety details for new supplement ingredient filings, recommending one safety narrative; comments accepted any time.
The US Food and Drug Administration (FDA) has issued final guidance on what supplement makers should tell it about new ingredients. Firms must still file at least 75 days before sale, and comments on the guidance are open at any time.
FDA announced the final guidance in a Federal Register notice on Oct. 20, 20261. It covers the identity and safety information that makers and sellers should include in a new dietary ingredient notification, a safety filing sent to FDA before a new supplement ingredient goes on sale1. FDA says it will keep finalizing other parts of its 2016 draft guidance on these filings2.
| At a glance | Details |
|---|---|
| What was published | Final guidance for industry, not a binding rule |
| Published on | 20 October 2026 (Federal Register) |
| Who must comply | Makers and sellers of new dietary ingredients and supplements that contain them |
| Feedback deadline / Effective date | No deadline: comments accepted at any time |
| Final rules / Next milestone | FDA to finalize other sections of the 2016 draft guidance |
What is a new dietary ingredient notification?
Under US food and drug law, some supplement firms must notify FDA before they sell a product3. This applies to a new dietary ingredient (NDI) that has not been in the food supply as food3. It also applies to a supplement that contains such an ingredient3.
The firm must file the notification at least 75 days before selling the product across state lines3. The filing must explain why the firm concluded the product will reasonably be expected to be safe as intended3. FDA calls this process its only opportunity to check these ingredients before they reach consumers2.
| Filing requirement | What the law requires |
|---|---|
| Who files | Maker or seller of the NDI or the supplement containing it3 |
| When | At least 75 days before interstate sale3 |
| What it must show | The basis for concluding the product is reasonably expected to be safe3 |
| Legal basis | Section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 190.63 |
What the new guidance covers
The guidance answers frequently asked questions about these filings1. It sets out the identity and safety information firms should include2. It also says when FDA recommends submitting different types of studies2.
The document finalizes three sections of the 2016 revised draft guidance1. They cover:
- identity information about the ingredient and the supplement
- history of use or other evidence of safety
- a summary of the basis for the firm’s safety conclusion
What changes for supplement makers
The biggest practical change concerns how firms present safety data. FDA dropped references to a separate "comprehensive safety profile"1. Instead, it recommends a single "safety narrative" for all filings, to ease the burden of submitting separate documents1.
FDA also added detail on what the safety narrative should contain1. It clarified when firms should submit extra evidence of safety and which types of studies it recommends1. Other edits aim to make the text clearer1.
The guidance reflects FDA’s current thinking and is not binding on FDA or the public1. Firms may use another approach if it meets the law and regulations1. The paperwork it describes is already approved under Office of Management and Budget (OMB) control number 0910-03301.
A guidance 15 years in the making
FDA first published a draft guidance on these filings on July 5, 20111. It received significant comments and issued a revised draft on Aug. 12, 20161. The comment period on that draft was extended to Dec. 12, 20161.
FDA chose to finalize separate sections of the 2016 draft one at a time2. The agency says this responds to public comments and makes the guidance easier to use2. It will mark on the 2016 draft which parts are now final2.
How to comment and what comes next
Comments on the final guidance can be sent at any time2. They go to Regulations.gov under docket number FDA-2025-D-65012. Written comments go to FDA’s Dockets Management Staff in Rockville, Maryland2.
FDA’s Office of Dietary Supplement Programs handles questions about the filing process2. The agency says it continues to prioritize finalizing the remaining parts of the 2016 draft2.
Key terms in plain words
| Term | Meaning |
|---|---|
| New dietary ingredient (NDI) | A supplement ingredient not previously in the food supply as food |
| NDI notification (NDIN) | The safety filing a firm sends FDA before selling a product with an NDI |
| Safety narrative | One written account of the evidence that the ingredient is safe |
| Guidance | FDA’s advice on how to meet the law, which is not itself binding |
| Docket | The public file where FDA collects comments on a document |
| Interstate commerce | Selling or shipping products across US state lines |
FDA’s next step is to finalize the remaining sections of its 2016 draft guidance2.
Sources
- ↩ Federal Register :: New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; Availability https://www.federalregister.gov/documents/2026/10/20/2026-21453/new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety-information-about
- ↩ FDA Issues Guidance on Identity and Safety Information for New Dietary Ingredient Notifications | FDA https://www.fda.gov/food/hfp-constituent-updates/fda-issues-guidance-identity-and-safety-information-new-dietary-ingredient-notifications
- ↩ Guidance for Industry: New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI | FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety